{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:00:25Z","timestamp":1793714425998,"version":"4.6.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T00:00:00Z","timestamp":1607040000000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Lymphovascular invasion (LVI), which includes vascular or lymphatic invasions, is a representative prognostic factor even in patients with resected stage IA non-small cell lung cancer (NSCLC). Because tegafur-uracil is effective on cancers with LVI, we conducted a multi-center single-arm phase II study to estimate the efficacy of adjuvant tegafur-uracil in patients with LVI-positive stage IA NSCLC.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Patients with completely resected LVI-positive stage IA NSCLC were registered. LVI was diagnosed by consensus of two of three pathologists. Adjuvant chemotherapy consisted of 2\u2009years of oral tegafur-uracil at 250\u2009mg\/m<jats:sup>2<\/jats:sup>\/day. Fifty-five patients from 7 institutions were enrolled from June 2007 to September 2012.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Among the 52 eligible patients, 36 (69.2%) completed the treatment course. There were 39 male and 13 female patients. The observation period was calculated as 562 to 3107\u2009days using the reverse Kaplan-Meier method. The 5-year overall and relapse free survival rates were 94.2 and 88.5% respectively, which were significantly better than that of any other studies conducted on patients with LVI-positive stage IA NSCLC. Notably, the overall survival rate was 15% better than that of our prior retrospective study. The retrospective analysis of stage IA NSCLC patients who had received an operation in the same period revealed that the 5-year overall survival rate of the LVI positive group was 73.6% when adjuvant chemotherapy was not applied. Among 55 safety analysis sets, 4 cases of grade 3 hepatic function disorder (9.1%) and 5 cases of grade 2 anorexia (10.9%) were most frequently observed. No grade 4 adverse effects were encountered.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>A 2-year course of oral tegafur-uracil administration is feasible and might have a significant benefit in the adjuvant treatment of LVI-positive stage IA NSCLC.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Trial registration<\/jats:title>\n<jats:p>UMIN identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/upload.umin.ac.jp\/cgi-open-bin\/ctr\/ctr_view.cgi?recptno=R000007002\">UMIN000005921<\/jats:ext-link>; Date of enrolment of the first participant to the trial: 19 June 2007; Date of registration: 5 July 2011 (retrospectively registered).<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12885-020-07691-7","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T13:04:10Z","timestamp":1607087050000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A single-arm, phase 2 study of adjuvant chemotherapy with oral tegafur-uracil for pathologically lymphovascular invasion positive stage IA non-small cell lung cancer: LOGIK0602 study"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8419-1478","authenticated-orcid":false,"given":"Tomoshi","family":"Tsuchiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Kamohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Muraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Nagayasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Takenoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Inada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoji","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomayoshi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Urabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaomi","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Akamine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Sugio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,4]]},"reference":[{"key":"7691_CR1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359\u201386.","journal-title":"Int J Cancer"},{"key":"7691_CR2","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1378\/chest.128.1.452","volume":"128","author":"P Yang","year":"2005","unstructured":"Yang P, Allen MS, Aubry MC, Wampfler JA, Marks RS, Edell ES, et al. Clinical features of 5,628 primary lung cancer patients: experience at mayo clinic from 1997 to 2003. Chest. 2005;128:452\u201362.","journal-title":"Chest"},{"key":"7691_CR3","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/0003-4975(95)00537-U","volume":"60","author":"RJ Ginsberg","year":"1995","unstructured":"Ginsberg RJ. Sublobectomy versus lobectomy for stage IA (T1a) non-small-cell lung cancer: a meta-analysis study. Ann Thorac Surg. 1995;60:615\u201323.","journal-title":"Ann Thorac Surg"},{"key":"7691_CR4","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/S0003-4975(01)02748-5","volume":"72","author":"K Suzuki","year":"2001","unstructured":"Suzuki K, Nagai K, Yoshida J, et al. Predictors of lymph node and intrapulmonary metastasis in clinical stage IA non-small cell lung carcinoma. Ann Thorac Surg. 2001;72:352\u20136.","journal-title":"Ann Thorac Surg"},{"key":"7691_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0169-5002(03)00285-X","volume":"42","author":"A Gajra","year":"2003","unstructured":"Gajra A, Newman N, Gamble GP, et al. Impact of tumor size on survival in stage IA non-small cell lung cancer: a case for subdividing stage IA disease. Lung Cancer. 2003;42:51\u20137.","journal-title":"Lung Cancer"},{"key":"7691_CR6","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/j.athoracsur.2004.04.061","volume":"78","author":"TTV Pechet","year":"2004","unstructured":"Pechet TTV, Carr SR, Collins JE, et al. Arterial invasion predicts early mortality in stage I non-small cell lung cancer. Ann Thorac Surg. 2004;78:1748\u201353.","journal-title":"Ann Thorac Surg"},{"key":"7691_CR7","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ejcts.2004.01.029","volume":"25","author":"Y Sakao","year":"2004","unstructured":"Sakao Y, Tomimitsu S, Takeda Y, et al. Carcinoembryonic antigen as a predictive factor for postoperative tumor relapse in early-stage lung adenocarcinoma. Eur J Cardiothorac Surg. 2004;25:520\u20132.","journal-title":"Eur J Cardiothorac Surg"},{"key":"7691_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.lungcan.2004.12.006","volume":"49","author":"H Kawai","year":"2005","unstructured":"Kawai H, Tada A, Kawahara M, et al. Smoking history before surgery and prognosis in patients with stage IA non-small-cell lung cancer - a multicenter study. Lung Cancer. 2005;49:63\u201370.","journal-title":"Lung Cancer"},{"key":"7691_CR9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.lungcan.2007.01.019","volume":"56","author":"T Tsuchiya","year":"2007","unstructured":"Tsuchiya T, Akamine S, Muraoka M, et al. Stage IA non-small cell lung cancer: vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy. Lung Cancer. 2007;56:341\u20138.","journal-title":"Lung Cancer"},{"key":"7691_CR10","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1378\/chest.06-1950","volume":"132","author":"T Tsuchiya","year":"2007","unstructured":"Tsuchiya T, Hashizume S, Akamine S, et al. Upstaging by vessel invasion improves the pathology staging system of non-small cell lung cancer. Chest. 2007;132:170\u20137.","journal-title":"Chest"},{"key":"7691_CR11","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jtcvs.2008.07.007","volume":"137","author":"K Miyoshi","year":"2009","unstructured":"Miyoshi K, Moriyama S, Kunitomo T, Nawa S. Prognostic impact of intratumoral vessel invasion in completely resected pathologic stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2009;137:429\u201334.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"7691_CR12","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1245\/s10434-011-1729-9","volume":"18","author":"K Funai","year":"2011","unstructured":"Funai K, Sugimura H, Morita T, et al. Lymphatic vessel invasion is a significant prognostic indicator in stage IA lung adenocarcinoma. Ann Surg Oncol. 2011;18:2968\u201372.","journal-title":"Ann Surg Oncol"},{"key":"7691_CR13","doi-asserted-by":"crossref","unstructured":"Kopfstein L, Christofori G. Metastasis : cell-autonomous mechanisms versus contributions by the tumor microenvironment.\u00a0Cell Mol Life Sci. 2006;63:449\u201368.","DOI":"10.1007\/s00018-005-5296-8"},{"key":"7691_CR14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.lungcan.2008.12.014","volume":"65","author":"S Hashizume","year":"2009","unstructured":"Hashizume S, Nagayasu T, Hayashi T, et al. Accuracy and prognostic impact of a vessel invasion grading system for stage IA non-small cell lung cancer. Lung Cancer. 2009;65:363\u201370.","journal-title":"Lung Cancer"},{"key":"7691_CR15","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.athoracsur.2013.11.002","volume":"97","author":"NM Mollberg","year":"2014","unstructured":"Mollberg NM, Bennette C, Howell E, et al. Lymphovascular invasion as a prognostic indicator in stage i non-small cell lung cancer: a systematic review and meta-analysis. Ann Thorac Surg. 2014;97:965\u201371.","journal-title":"Ann Thorac Surg"},{"key":"7691_CR16","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1097\/JTO.0b013e31825cca6e","volume":"7","author":"Y Shimada","year":"2012","unstructured":"Shimada Y, Saji H, Yoshida K, et al. Pathological vascular invasion and tumor differentiation predict cancer recurrence in stage ia non-small-cell lung cancer after complete surgical resection. J Thorac Oncol. 2012;7:1263\u201370.","journal-title":"J Thorac Oncol"},{"key":"7691_CR17","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1093\/icvts\/ivs163","volume":"15","author":"T Ito","year":"2012","unstructured":"Ito T, Murakawa T, Sato H, et al. Simple preoperative computed tomography image analysis shows good predictive performance for pathological vessel invasion in clinical stage IA non-small cell lung cancer. Interact Cardiovasc Thorac Surg. 2012;15:633\u20138.","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"7691_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.lungcan.2013.04.016","volume":"81","author":"Y Kudo","year":"2013","unstructured":"Kudo Y, Saji H, Shimada Y, et al. Proposal on incorporating blood vessel invasion into the T classification parts as a practical staging system for stage I non-small cell lung cancer. Lung Cancer. 2013;81:187\u201393.","journal-title":"Lung Cancer"},{"key":"7691_CR19","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.3892\/ol.2014.2284","volume":"8","author":"H Hirano","year":"2014","unstructured":"Hirano H, Maeda H, Takeuchi Y, et al. Lymphatic invasion of micropapillary cancer cells is associated with a poor prognosis of pathological stage IA lung adenocarcinomas. Oncol Lett. 2014;8:1107\u201311.","journal-title":"Oncol Lett"},{"key":"7691_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13000-015-0249-5","volume":"10","author":"R Hamanaka","year":"2015","unstructured":"Hamanaka R, Yokose T, Sakuma Y, et al. Prognostic impact of vascular invasion and standardization of its evaluation in stage I non-small cell lung cancer. Diagn Pathol. 2015;10:1\u201310.","journal-title":"Diagn Pathol"},{"key":"7691_CR21","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa032792","volume":"350","author":"H Kato","year":"2004","unstructured":"Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil\u2013Tegafur for adenocarcinoma of the lung. N Engl J Med. 2004;350:1713\u201321.","journal-title":"N Engl J Med"},{"key":"7691_CR22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1023\/A:1014059528046","volume":"4","author":"Y Basaki","year":"2001","unstructured":"Basaki Y, Chikahisa L, Aoyagi K, Miyadera K, Yonekura K. [gamma]-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. Angiogenesis. 2001;4:163\u201373.","journal-title":"Angiogenesis"},{"key":"7691_CR23","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1136\/jcp.2003.013508","volume":"57","author":"TC Mineo","year":"2004","unstructured":"Mineo TC, Ambrogi V, Baldi A, et al. Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol. 2004;57:591\u20137.","journal-title":"J Clin Pathol"},{"key":"7691_CR24","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1097\/JTO.0b013e31812f3c1a","volume":"2","author":"P Goldstraw","year":"2007","unstructured":"Goldstraw P, Crowley J, Chansky K, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2:706\u201314.","journal-title":"J Thorac Oncol"},{"key":"7691_CR25","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jtho.2018.02.015","volume":"13","author":"S Toyooka","year":"2018","unstructured":"Toyooka S, Okumura N, Nakamura H, et al. A multicenter randomized controlled study of paclitaxel plus carboplatin versus Oral uracil-Tegafur as the adjuvant chemotherapy in resected non\u2013small cell lung cancer. J Thorac Oncol. 2018;13:699\u2013706.","journal-title":"J Thorac Oncol"},{"key":"7691_CR26","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/JTO.0b013e3181c814e7","volume":"5","author":"J-Y Douillard","year":"2010","unstructured":"Douillard J-Y, Tribodet H, Aubert D, et al. Adjuvant Cisplatin and Vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the lung adjuvant Cisplatin evaluation. J Thorac Oncol. 2010;5:220\u20138.","journal-title":"J Thorac Oncol"},{"key":"7691_CR27","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1056\/NEJMoa043623","volume":"352","author":"T Winton","year":"2005","unstructured":"Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352:2589\u201397.","journal-title":"N Engl J Med"},{"key":"7691_CR28","doi-asserted-by":"crossref","unstructured":"Tanaka F, Yanagihara K, Otake Y, et al. Angiogenesis and the efficacy of postoperative administration of UFT in pathologic stage I non-small cell lung cancer.\u00a0Cancer Sci. 2004;95:371\u20136.","DOI":"10.1111\/j.1349-7006.2004.tb03218.x"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07691-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-020-07691-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07691-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T13:15:38Z","timestamp":1607087738000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07691-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7691"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07691-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"10 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the institutional review board at each site. The ethics committees are review boards of Oita Prefectural Hospital, Japan Community Health care Organization Isahaya General Hospital, Kumamoto University Hospital, National Hospital Organization Kyushu Cancer Center, National Hospital Organization Omuta Hospital, Kyushu University Hospital, Nagasaki Prefecture Shimabara Hospital and Oita University. Patients decided whether or not they would participate in the trial after being given a detailed explanation, and written informed consent was obtained from all patients prior to enrolment. All procedures performed in studies were in accordance with the 1964 Helsinki declaration and tis later amendment. This study also adheres to CONSORT guidelines.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Mitsuhiro Takenoyama received honoraria from AstraZeneca, Bristol-Myers Squibb, Chugai Pharmaceutical, Covidien Japan, Eli Lilly Japan, Kyowa Hakko Kirin, MSD, Nippon Boehringer Ingelheim, Novartis Pharma, Ono Pharmaceutical, Pfizer Japan and Taiho Pharmaceutical. He also received research funding from AstraZeneca, Bristol-Myers Squibb, Chugai Pharmaceutical, Covidien Japan, Eli Lilly Japan, Johnson & Johnson, Kyowa Hakko Kirin, KM biologics, MSD, Nippon Boehringer Ingelheim, Novartis Pharma, Ono Pharmaceutical and Taiho Pharmaceutical. Kenji Sugio received research funding from MSD.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1192"}}